Advertising

CVE:ACST

2.15
0.05 (2.27%) 1d
0
Showing 1 to 15 of 19 entries
COMMENT

The krill oil lipid trial did not work as expected. The overall portfolio is quite attractive. Over the coming year, there may be opportunities. However, there are other opportunities in other companies like ATE, which he owns.

Consumer Products
PARTIAL SELL
They have a product that uses fats to accelerate the effectiveness of other drugs. They have done tests at over 30 locations for a new drug that did not yield conclusive results. They are re-testing. He has sold a portion of his holdings.
Consumer Products
BUY
It uses lipids having greater bio-availability to reduce cholesterol. The stock went through a hair cut recently. Testing results are being further investigated but are positive.
Consumer Products
WAIT
Develops CaPre to treat high cholesterol. One of the most promising companies. Strangely, the drug performed the same as the placebo. They'll have to raise more money. Right now, it's in no-man's land. Failure on a trial is devastating to a small company. Look at it in the fall.
Consumer Products
HOLD
They are working on testing a drug to use krill oil to help other drugs in the fight against cholesterol. Some recent research has been unclear among testers -- another test coming out in four months. He owns this personally.
Consumer Products
SELL
It highlights the pharma industry. In Canada there are a lot of tax credits that are applicable to Canadian Pharma companies. You can't say this is predictable. They went through the trials and it did not work. Phase three is for that. They still have some cash and some science. Stocks in this position usually flat lines for a while. He feels it is better to come out and get back in later.
Consumer Products
RISKY BUY
They're working on a phase two test of a new drug, but the results are delayed, which has hammered the stock by half, though it's moved up 16% today. Results should be released in mid/late-January and he expects them to be positive. The drug will address a huge population who suffers high cholesterol. He sees a $10 target price, if the result is good and all goes well. Very speculative.
Consumer Products
BUY
Quite likes the company. Potentially revolutionary drug called Capri has phase 3 trials coming up, and if those validate earlier phases, stock could have a lot of upside. Really likes it here. (Analysts’ price target is $5.52)
Consumer Products
BUY
They use the lipid from krill oil to strengthen action of another drug. Early indications seem very promising. The results should be out soon. One batch before the end of the year, and another in the new year. If the trial is successful, we could see a significant increase in the price.
Consumer Products
STRONG BUY
It's finally breaking out after going nowhere for a while. They're doing phase 3 trials now on their drug and should complete the results by December. That's why investors are pushing this stock up. He expects good results and be accretive. A $200 million company worth north of $1 billion. Caveat: biotech stocks are volatile.
Consumer Products
COMMENT
A Top Pick of his son's. They use krill to give shrimp their pink colour. They are looking to combine this with a pharma drug to create synergies. If successful, the stock price analysts suggest it could go to $8 per share. They are doing FDA testing.
Consumer Products
BUY

Pretty disappointing after last fall's announcement to have an Asian pharma company come in and get the rights to CaPre, their phase-3 development drug to treat cholesterol. It looked promising, but ACST hold off on the deal after a few new parties showed interest in CaPre. The market is disappointed the deal didn't happen and punished this stock. He believes this company could be worth $1 billion in two three years. The promise is still there, but you have to wait. Watch the phase 3 drug trials into next year.

Consumer Products
TOP PICK

A company with no revenue now. Drug developer. They are into phase 3 trials. A $33 million market cap company with half that in cash in their balance sheet. Probably going to be taken out by a large pharma once the drug is approved. (Analysts’ price target is $5.21)

Consumer Products
STRONG BUY

Got beaten up recently, because they just did a financing. (He has 3% of the financing.) A compelling opportunity and a great entry point. They are going to be initiating phase 3 trials this month. Just raised some money and have enough to do the trial now. In negotiations with a big Chinese Pharma in terms of licensing Asian rights. Has been presented with an opportunity for about $125 million deal with the Chinese, which they are still negotiating. They have the cash on the balance sheet, so there are no near-term financial pressures.

Consumer Products
BUY

A spin-out out of Neptune (NEPT-T), which still owns 35% of the company. There are positive developments going on and they are getting very close to going forward with phase 3. Discussions have been going on with the FDA. It’s fallen off the radar screen and there isn’t much in terms of analysts’ coverage. Expects there will be news this fall and winter which should really catalyze the stock. A good time to accumulate the stock.

Consumer Products
Showing 1 to 15 of 19 entries

Acasti Pharma(ACST-X) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Acasti Pharma is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Acasti Pharma(ACST-X) Frequently Asked Questions

What is Acasti Pharma stock symbol?

Acasti Pharma is a Canadian stock, trading under the symbol ACST-X on the TSX Venture Exchange (ACST-CV). It is usually referred to as TSXV:ACST or ACST-X

Is Acasti Pharma a buy or a sell?

In the last year, there was no coverage of Acasti Pharma published on Stockchase.

Is Acasti Pharma a good investment or a top pick?

Acasti Pharma was recommended as a Top Pick by on . Read the latest stock experts ratings for Acasti Pharma.

Why is Acasti Pharma stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Acasti Pharma worth watching?

0 stock analysts on Stockchase covered Acasti Pharma In the last year. It is a trending stock that is worth watching.

What is Acasti Pharma stock price?

On 2021-10-15, Acasti Pharma (ACST-X) stock closed at a price of $2.15.